Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Ontology highlight
ABSTRACT: Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
SUBMITTER: Titanji BK
PROVIDER: S-EPMC7337637 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA